Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 25;21(1):176.
doi: 10.1186/s12906-021-03341-y.

Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro

Affiliations

Bioactive fractions and compound of Ardisia crispa roots exhibit anti-arthritic properties mediated via angiogenesis inhibition in vitro

Joan Anak Blin et al. BMC Complement Med Ther. .

Abstract

Background: Ardisia crispa (Thunb.) A.DC (Primulaceae), is a medicinal herb traditionally used by Asian people as remedies to cure inflammatory related diseases, including rheumatism. The plant roots possess various pharmacological activities including antipyretic, anti-inflammation and antitumor. Previous phytochemical studies of the plant roots have identified long chain alkyl-1,4-benzoquinones as major constituents, together with other phytochemicals. Hexane fraction of the plant roots (ACRH), was previously reported with anti-angiogenic and anti-arthritic properties, while its effect on their anti-arthritic in vitro, is yet unrevealed. Considering the significance of angiogenesis inhibition in developing new anti-arthritic agent, thus we investigated the anti-arthritic potential of Ardisia crispa roots by suppressing angiogenesis, in vitro.

Methods: Ardisia crispa roots hexane extract (ACRH) was prepared from the plant roots using absolute n-hexane. ACRH was fractionated into quinone-rich fraction (QRF) and further isolated to yield benzoquinonoid compound (BQ), respectively. In vitro experiments using VEGF-induced human umbilical vein endothelial cells (HUVECs) and IL-1β-induced human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) were performed to evaluate the effects of these samples on VEGF-induced HUVECs proliferation and tube formation, and towards IL-1β-induced HFLS-RA proliferation, invasion, and apoptosis, respectively. Therapeutic concentrations (0.05, 0.5, and 5 μg/mL) tested in this study were predetermined based on the IC50 values obtained from the MTT assay.

Results: ACRH, QRF, and BQ exerted concentration-independent antiproliferative effects on VEGF-induced HUVECs and IL-1β-induced HFLS-RA, with IC50 values at 1.09 ± 0.18, 3.85 ± 0.26, and 1.34 ± 0.16 μg/mL in HUVECs; and 3.60 ± 1.38, 4.47 ± 0.34, and 1.09 ± 0.09 μg/mL in HFLS-RA, respectively. Anti-angiogenic properties of these samples were verified via significant inhibition on VEGF-induced HUVECs tube formation, in a concentration-independent manner. The invasiveness of IL-1β-induced HFLS-RA was also significantly inhibited in a concentration-independent manner by all samples. ACRH and BQ, but not QRF, significantly enhanced the apoptosis of IL-1β-induced HFLS-RA elicited at their highest concentration (5 μg/mL) (P < 0.05).

Conclusions: These findings highlight the bioactive fractions and compound from Ardisia crispa roots as potential anti-arthritic agents by inhibiting both HUVECs and HFLS-RA's cellular functions in vitro, possibly mediated via their anti-angiogenic effects.

Keywords: Angiogenesis; Ardisia crispa; Human fibroblast-like synoviocytes for rheumatoid arthritis; Human umbilical vein endothelial cells; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Concentration-response graphs showing the antiproliferative effect of a ACRH, b QRF, and c BQ towards VEGF-induced human umbilical vein endothelial cells (HUVECs) after 24 h of incubation. Data were expressed as percentage mean ± SEM (n = 3) of viable cells normalized to 100% cell viability in the negative control and were analyzed using one-way ANOVA followed by Tukey HSD post-hoc test. Significant differences (P < 0.05) are indicated by different letters between different concentrations
Fig. 2
Fig. 2
Concentration-response graphs showing the antiproliferative effect of a ACRH, b QRF, and c BQ, respectively towards IL-1β-induced human fibroblast-like synoviocytes for rheumatoid arthritis (HFLS-RA) after 24 h of incubation. Data were expressed as percentage mean ± SEM (n = 3) of viable cells normalized to 100% cell viability in the negative control and were analyzed using one-way ANOVA followed by Tukey HSD post-hoc test. Significant differences (P < 0.05) are indicated by different letters between different concentrations
Fig. 3
Fig. 3
a Representative fluorescent images (40 × magnification) showing inhibitory activities of ACRH, QRF, and BQ on HUVECs tube formation after 16 h treatment. b Quantitative data of VEGF-induced HUVECs tube formation post treatments with all samples for 16 h. Data were represented as the percentage of tube lengths relative to negative control (normalized to 100% tubular formation) and expressed as mean ± SEM (n = 3). Data were analyzed using one-way ANOVA followed by Tukey HSD post-hoc test. Significant differences (P < 0.05) are indicated by different letters between different groups
Fig. 4
Fig. 4
a Illustrated micrographs (10 × magnification) showing anti-invasive effects of ACRH, QRF, and BQ on HFLS-RA invasion. b Quantitative data of HFLS-RA cell invasion post treatments with all samples for 22 h. Data were represented as the percentage of invaded cells relative to negative control (at 100% invading cells) and expressed as mean ± SEM (n = 3). Data were analyzed using one-way ANOVA followed by Tukey HSD post-hoc test. Significant differences (P < 0.05) are indicated by different letters between different groups
Fig. 5
Fig. 5
The dot plots showing the cell distribution of IL-1β-induced HFLS-RA as determined by Annexin V-PI staining. The cells were induced with IL-1β (10 ng/mL) and concurrently exposed to various concentrations (0.05, 0.5, and 5 μg/mL) of ACRH, QRF, and BQ respectively for 24 h

Similar articles

Cited by

References

    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi: 10.1016/s0140-6736(16)30173-8. - DOI - PubMed
    1. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. doi: 10.1002/acr.22783. - DOI - PubMed
    1. Henrique da Mota LM, Afonso Cruz B, Viegas Brenol C, Alves Pereira I, Rezende-Fronza LS, Barros Bertolo M, et al. Guidelines for the drug treatment of rheumatoid arthritis. Rev Bras Reumatol. 2013;53(2):158–183. doi: 10.1590/S0482-50042013000200004. - DOI - PubMed
    1. Xiang G, Jinyu J, Zhitao F, Xiaoqiang H, Yanan L, Zhigang M. A network pharmacology approach to explore the potential targets underlying the effect of sinomenine on rheumatoid arthritis. Int Immunopharmacol. 2020;80(106201). 10.1016/j.intimp.2020.106201. - PubMed
    1. Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford) 2017;56(3):417–425. doi: 10.1093/rheumatology/kew442. - DOI - PubMed